Bovine Tuberculosis Therapeutics Market Size, Share, and Growth Forecast 2026 - 2033

The global bovine tuberculosis therapeutics market size is likely to be valued at US$96 million in 2026 and is estimated to reach US$180 million by 2033, growing at a CAGR of 9.4% during the forecast period from 2026 to 2033, driven by progress in cattle vaccination and strong government eradication programs. Wildlife vaccination is also augmenting demand.

Driver - Zoonotic Risk and Persistent Herd Infection to Lift Control Spending

Bovine tuberculosis harms animal health and human safety. A 2024 systematic review in Frontiers in Public Health reported that about 140,000 people contracted zoonotic tuberculosis (TB) worldwide in 2019. About 11,400 deaths followed. The authors say zoonotic TB is under-reported in the regions they studied. A WHO, FAO, and WOAH road map, launched in 2017 with the Union, set 10 priority actions to reduce transmission. WHO data cited then showed more than 140,000 people falling ill and more than 12,000 dying each year.

Herd data show a widespread distribution. A 2018 meta-analysis of 44 studies and 82,419 cows and buffaloes found a 7.3% pooled prevalence in India. State estimates ranged from 0.4% to 51.2%. A 2021 meta-analysis of 100 studies found 2.4% prevalence in Chinese dairy cattle from 2010 to 2019. Scale farms had a higher prevalence, at 3.7%. Such figures keep demand for control tools high.

Cattle Vaccine Progress to Augment Long-term Market Growth

Vaccine trials are moving forward. The U.K. Animal and Plant Health Agency (APHA) ran Phase 1 of its cattle BCG and DIVA skin test field trials from June 2021 to May 2022. Phase 2 ran from January 2023 to December 2024 with over 600 cattle from seven herds. Phase 3 includes at least 10 farms and 750 animals and is due to be completed in 2026.

Efficacy data is bolstering growth. A 2024 study in Science, run in Ethiopia, found BCG vaccination reduced transmission by almost 90% in dairy herds, according to the University of Cambridge. The U.K. TB Hub cites a 74% reduction in onward transmission and 89% total efficacy. The two sources report different figures, so readers should check the original paper. Strong data can support regulatory approval.

Restraint - Test-and-Slaughter Rules and Trade Limits May Hold Back Vaccine Use

Current rules favor testing and slaughter. The U.K. TB Hub says BCG causes about 80% of vaccinated cattle to react to the tuberculin test. WOAH standards make no provision for cattle TB vaccination, as it conflicts with tuberculin-based trade and control. U.K. law also bars cattle vaccination without written ministerial consent. A DIVA test is needed to separate vaccinated from infected animals. The current tuberculin test cannot do this. Germany also has no regular dedicated cattle monitoring program since it gained TB-free status, so demand there is limited.

Approval timelines have slipped. Defra had said the vaccine and DIVA test would be commercially available in 2025. In March 2024, Farmers Weekly reported the target moved to the next few years. Both products need U.K. marketing authorization, and the DIVA test needs validation to WOAH standards. A 90-day withdrawal period applies to meat and offal from vaccinated cattle.

Opportunity - DIVA-enabled Vaccination to Support Eradication Targets

Governments have clear goals. APHA links the vaccine and DIVA test to eradicating bovine TB by 2038 in England and 2041 in Wales. On-farm Phase 3 work at the remaining five farms was due to finish by summer 2026. If trials succeed, rollout could follow within a few years. Early use may focus on restricted herds that sell cattle only for slaughter. The DIVA test can separate vaccinated from infected cattle, which the current tuberculin test cannot. Phase 3 now covers 11 farms in England and Wales and at least 700 animals.

The cost of the disease supports uptake. In England, 2,139 new herd incidents were recorded in the 12 months to December 2025, down 14%. About 20,494 cattle were slaughtered for TB control, and 1,550 herds were under restriction. Vaccines that cut incidents can save compensation costs. This makes government a key buyer.

Wildlife Vaccination and Surveillance Programs to Open New Demand Channels

Wildlife control is expanding. Defra awarded AJ Vaccines a contract to supply BadgerBCG from November 1, 2025 to September 30, 2028. The contract value was GBP 1,532,362.88 excluding VAT. It supports the Badger Vaccination Field Force, due to start in 2026. The award was made directly on single-supplier technical grounds. More than 4,000 badgers were vaccinated in 2024.

Deer are also a reservoir in some regions. Michigan officials say bovine TB is present in white-tailed deer within the state's Modified Accredited Zone. The state relies on routine herd testing, animal identification, movement certificates, and wildlife biosecurity. Future tools for wildlife could widen the market beyond cattle. Surveillance tools also create linked demand.

Treatment Type Insights

Vaccines are predicted to lead with a share of about 56.8% in 2026, as eradication programs favor prevention. BCG is the main vaccine in trials, and AJ Vaccines supplies cattle BCG for U.K. field trials. Government funding and trial spending support revenue. Commercial sales depend on regulatory approval.

Immunomodulators and host-directed therapies are estimated to be the fastest-growing treatment type over the forecast period, from a very small base. Few public datasets track these products, so this is our analyst view. Interest comes from the limits of vaccines and tests. Clinical proof and regulatory clearance will decide how fast this segment scales.

Animal Type Insights

Dairy cattle are anticipated to dominate with a share of around 62.7% in 2026, as dairy herds are tested often and have high economic value. Michigan found a dairy herd with bovine TB in February 2026 after a cow tested positive at a processing plant. Importers also require proof that milk comes from TB-free herds or is pasteurized. This keeps focus on dairy herds.

Beef cattle are expected to be the fastest-growing animal type over the forecast period, as slaughter-bound herds are likely early users of vaccination. The U.K. TB Hub says deployment would likely start in restricted herds that sell cattle only for slaughter. Michigan's November 2025 detection was in a beef herd. Trade rules also add pressure for control in beef herds.

Europe Bovine Tuberculosis Therapeutics Market Trends

Europe is predicted to dominate in 2026 globally with a share of approximately 34.6%, supported by government-funded vaccine trials, strong surveillance, and clear eradication goals. England and Wales target eradication by 2038 and 2041. Germany is one of 17 EU member states with officially TB-free status. Policy, not private demand, drives this region. Wales follows a similar path to England under shared field trials run by APHA for Defra, the Welsh Government, and the Scottish Government.

U.K. Bovine Tuberculosis Therapeutics Market Trends

In Europe, a share of nearly 31.2% is predicted to be held by the U.K. in 2026, as it runs the most active cattle vaccine program in the region. In England, new herd incidents fell 14% to 2,139 in the 12 months to December 2025. Defra described the data as clear, sustained progress. The U.K. also funds badger vaccination.

Germany Bovine Tuberculosis Therapeutics Market Trends

Germany is likely to hold a share of about 19.4% in Europe in 2026. The country has been officially free of cattle TB since 1997, according to the Federal Institute for Risk Assessment. Four cattle herds had outbreaks in 2022, with a prevalence below 0.003%. Only 43 of 4,076 human TB cases in 2022 were caused by M. bovis. Demand is therefore small and surveillance-led. Three of the four 2022 outbreaks were caused by M. caprae and one by M. bovis.

Asia Pacific Bovine Tuberculosis Therapeutics Market Trends

Asia Pacific is anticipated to be the fastest-growing region globally in 2026, driven by its large cattle and buffalo populations. Seven countries in South-East Asia and eleven in the Western Pacific reported bovine TB in domestic animals, according to a 2024 review. Under-reporting remains a concern. Rising control efforts should lift demand over time. Most studies in the region rely on tuberculin skin tests, so better tools could improve detection and demand for treatment and prevention.

China Bovine Tuberculosis Therapeutics Market Trends

China will likely lead in Asia Pacific in 2026 with a share of about 36.4%. A meta-analysis of 100 studies found 2.4% pooled prevalence in dairy cattle from 2010 to 2019. Prevalence fell to 0.8% in studies from 2017 onward. Scale farms had higher prevalence than free-range farms, and heifers had the highest rate at 27.1%.

India Bovine Tuberculosis Therapeutics Market Trends

In 2026, India is projected to account for a share of just about 34.1% in Asia Pacific, owing to a large dairy herd and high bovine TB prevalence. A 2018 meta-analysis pooled prevalence at 7.3% across 44 studies. State figures ranged from 0.4% in Uttarakhand to 51.2% in Pondicherry. Most studies used tuberculin skin tests.

North America Bovine Tuberculosis Therapeutics Market Trends

North America is predicted to hold a share of approximately 21.3% in 2026 globally, supported by strong surveillance and a well-funded animal health system. Michigan's November 2025 case was the state's 84th cattle herd with bovine TB since 1998. It was also the first detected since January 2025. The region relies on test-and-remove and wildlife management. The Modified Accredited Zone covers four counties: Alcona, Alpena, Montmorency, and Oscoda. The rest of Michigan is an accredited free zone.

U.S. Bovine Tuberculosis Therapeutics Market Trends

In North America, a share of nearly 80.4% is expected to be held by the U.S. in 2026, as it has a large cattle industry and federal-state TB programs. In February 2026, Michigan announced a positive dairy herd in Charlevoix County, found through slaughter surveillance. Whole-herd testing found additional cases. Control relies on herd testing, animal identification, and movement certificates. Wildlife biosecurity programs add another layer.

The global bovine tuberculosis therapeutics market is highly concentrated and public-sector led. AJ Vaccines supplies cattle BCG for U.K. field trials and BadgerBCG for Defra. Lionex supplies pilot batches of the DIVA skin test. APHA developed the DIVA test with three defined antigens. AJ Vaccines is a Danish company and the only organization licensed to produce BadgerBCG.

Competition is shifting toward approval and manufacturing readiness. Final approval needs GMP-standard manufacture of the DIVA test. Large animal health companies could enter once rules allow vaccination. Players with regulatory experience, secure supply, and government ties are better placed to grow.

Key Industry Developments:

• In July 2026, the U.K. government confirmed in a parliamentary response that government-funded trials of the CattleBCG vaccine and its companion DIVA skin test were continuing, with the final planned phase expected to be completed by 2027. The government also referenced a proposed bovine TB control strategy for England that set an ambition to deploy the vaccine and diagnostic test by 2030. The update reinforced the UK's continued investment in cattle vaccination as a potential component of long-term bovine TB control, while confirming that further trial and regulatory work remained necessary before deployment.
• In June 2026, the World Organization for Animal Health (WOAH) announced that its Biological Standards Commission had concluded its evaluation of candidate replacements for the International Standard Bovine Tuberculin. Following extensive international studies, the proposed candidates did not meet the required potency levels, prompting WOAH to relaunch a global call for new candidate materials.
• In January 2025, researchers published a study in Scientific Reports investigating orally administered live BCG and heat-inactivated Mycobacterium bovis vaccines in bison exposed to experimental bovine tuberculosis infection. The study explored alternative vaccination strategies for susceptible wildlife populations, which can act as reservoirs of infection and complicate livestock disease-control programs. The findings provided further evidence supporting research into oral vaccination approaches for bovine TB management, although the results in bison should not be interpreted as proof of efficacy in cattle or as evidence of a commercially launched therapeutic product.